

# KEYPAD Trial News

[www.anzup.org.au](http://www.anzup.org.au)

## Welcome to the 5<sup>th</sup> KEYPAD study newsletter – congratulations on reaching 50% milestone

We would like to take this opportunity to thank all the KEYPAD investigators and trial teams for your amazing efforts throughout 2019. This week we reached a significant milestone – reaching 50% patient recruitment. Well done to everyone for your continuous hard work! Congratulations to Dr Abhishek Joshi and the team at Townsville Hospital for registering their first patient within three months of site activation.

### Site Accrual

Recruitment is progressing well with a total of 35 patients registered. Please remember to discuss the study at MDT and encourage colleagues to refer any eligible patients. Please continue to contact us the KEYPAD team (<mailto:keypad@ctc.usyd.edu.au>) with any eligibility or study questions.

Sites	Patients enrolled to date
St George Hospital	5
Calvary Mater Newcastle	5
Concord Repatriation General Hospital	5
Sunshine Coast University Hospital	4
Royal Brisbane & Women's Hospital	3
Flinders Medical Centre	3
Ballarat Oncology and Haematology Services	2
Fiona Stanley Hospital	2
Peter MacCallum Cancer Centre	1
Icon Cancer Care	1
Northern Cancer Institute	1
Eastern Health / Box Hill	1
Monash Health (Monash Medical Centre Clayton of Monash Health)	1
Townsville	1
Border Medical Oncology Research Unit	0
St Vincent's Hospital Sydney	In start-up
<b>Total</b>	<b>35</b>

### KidnEY cancer Pembrolizumab And Denosumab (KEYPAD)

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP 1601)

### ANZUP & CTC Christmas shutdown

ANZUP will close from 5.00pm, Friday 20<sup>th</sup> December 2019 and will re-open on Thursday 2<sup>nd</sup> January 2020.

The NHMRC Clinical Trials Centre will officially close from 5.00pm, Friday 20<sup>th</sup> December 2019 and will re-open at 9.00am, Tuesday 7<sup>th</sup> January 2020.

**If you require emergency assistance with a randomisation, registration or to process a SUSAR please phone +61 406 384 367. All other enquiries will be responded to on Tuesday, 7<sup>th</sup> January 2020.**

### Data entry and site payments


Please update your patient records on InForm and resolve any data queries to ensure site and per-patient payments scheduled in early 2020 are made in full.

*KEYPAD is a collaboration between ANZUP and NHMRC Clinical Trials Centre.*

*This investigator initiated ANZUP study has been supported both financially and with study drug by MSD and Amgen. ANZUP is supported by the Australian Government through Cancer Australia.*

## News item: a new drug for future trials?

The KEYPAD trial is testing the idea of combining two different antibody drugs to see if they can improve cancer treatment; but some of the researchers who first proposed this idea have taken it one step further; combining the two drugs in one antibody. In this (<https://onlinelibrary.wiley.com/doi/full/10.1002/cti2.1081>) paper these scientists have created a “bispecific” antibody, that recognises the RANKL and PD1 targets, one on each arm of the antibody. This new antibody has been designed and tested in mice as a proof-of-concept, but already shows impressive results.



## The AUTO-CHECK

- The AUTO-CHECK substudy will close to new patient recruitment on Thursday 19-Dec-2019. For any new patients enrolled to KEYPAD after 19-Dec-2019, **do not collect AUTO-CHECK blood samples**. A revised lab manual will be emailed to you by 19-Dec-2019.
- For existing patients (enrolled up to 19-Dec-2019), continue to collect AUTO-CHECK blood samples until ACD tubes expire on 30-Jun-2020.
- The AUTO-CHECK central laboratories will be closed for the holiday season from Monday 23 December 2019 to Monday 6 January 2020 inclusive. Do not collect or send AUTO-CHECK blood samples on or between these dates.
  - Last AUTO-CHECK blood collection date for 2019: Thursday 19-Dec-2019
  - First AUTO-CHECK blood collection date for 2020: Monday 6-Jan-2020
- REMINDER TO ALL AUTO-CHECK INVESTIGATORS:** Please remain vigilant for IRAEs throughout follow up – including beyond the 90 day safety reporting period. Collect AUTO-CHECK bloods whenever a significant IRAE occurs (ideally before starting steroids) or at the next clinic visit - or at any subsequent clinic visit (earlier is better, but it’s never too late). Thank you for your ongoing support!

## KEYPAD real-time ambient Tissue Block shipments to Hunter Cancer Biobank

The KEYPAD central laboratories will be closed for the holiday season from Thursday 19 December 2019 to Monday 6 January 2020 inclusive.

- Last date to ship tissue blocks for 2019: **Tuesday 17-Dec-2019**
- First date to ship tissue blocks in 2020: **Tuesday 7-Jan-2020**

**Do not ship tissue blocks on or between Wednesday 18-Dec-2019 to Monday 6-Jan-2020 inclusive.**



**ANNUAL SCIENTIFIC MEETING**  
ADELAIDE CONVENTION CENTRE  
19-21 JULY 2020

## KEYPAD key contacts

- Clinical trial operations, CTC E: [keypad@ctc.usyd.edu.au](mailto:keypad@ctc.usyd.edu.au) and [kate.ford@ctc.usyd.edu.au](mailto:kate.ford@ctc.usyd.edu.au)
- Coordinating PI: Craig Gedye E: [craig.gedye@newcastle.edu.au](mailto:craig.gedye@newcastle.edu.au)
- Sponsor queries (payments, contracts) Nisha Rana E: [nisha.rana@anzup.org.au](mailto:nisha.rana@anzup.org.au)
- Trial pages: <https://www.anzup.org.au/content.aspx?page=keypad>